Sensus Healthcare (SRTS) awards 40,000 restricted shares to director

Rhea-AI Filing Summary

Sensus Healthcare reported an insider stock grant to one of its leaders. Director and officer Michael Sardano, who serves as President and General Counsel, acquired 40,000 shares of common stock on 12/12/2025 through a restricted stock award under the Sensus Healthcare, Inc. 2017 Equity Incentive Plan.

The restricted shares will vest in four equal annual installments starting on the first anniversary of the grant date. Following this grant, Sardano directly beneficially owns 158,839 shares of Sensus Healthcare common stock, with an additional 1,000 shares held by his spouse, for which he disclaims beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sardano Michael

(Last) (First) (Middle)

851 BROKEN SOUND PARKWAY NW

STE. 215

(Street)

BOCA RATON FL 33487

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sensus Healthcare, Inc. [ SRTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND GENERAL COUNSEL

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		40,000(1)	A	$0	158,839	D
Common Stock								1,000	I	spouse(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 40,000 shares of restricted stock granted to the reporting person pursuant to the Sensus Healthcare, Inc. 2017 Equity Incentive Plan, all of which will vest in four equal annual installments beginning on the first anniversary of the date of grant.

2. Shares held by the reporting person's spouse, as to which the reporting person disclaims beneficial ownership.

	/s/ Michael Sardano	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sensus Healthcare (SRTS) report in this filing?

The filing shows that Michael Sardano, a director and the President and General Counsel of Sensus Healthcare, acquired 40,000 shares of common stock on 12/12/2025 through a restricted stock grant.

What type of shares did Michael Sardano receive from Sensus Healthcare (SRTS)?

He received 40,000 shares of restricted common stock granted under the Sensus Healthcare, Inc. 2017 Equity Incentive Plan, as noted in the explanation of responses.

How do the 40,000 restricted shares for Sensus Healthcare (SRTS) vest?

The 40,000 restricted shares will vest in four equal annual installments, beginning on the first anniversary of the 12/12/2025 grant date.

How many Sensus Healthcare (SRTS) shares does Michael Sardano own after the transaction?

After the reported transaction, Michael Sardano beneficially owns 158,839 shares of Sensus Healthcare common stock directly. An additional 1,000 shares are held by his spouse, for which he disclaims beneficial ownership.

What is Michael Sardanos role at Sensus Healthcare (SRTS)?

Michael Sardano is listed as both a Director and an Officer of Sensus Healthcare, serving as President and General Counsel, according to the relationship section.

At what price were the 40,000 Sensus Healthcare (SRTS) shares reported on this Form 4 acquired?

The table indicates the 40,000 shares of common stock were acquired at a price of $0, consistent with a restricted stock grant rather than an open-market purchase.